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Purpose: Kawasaki disease (KD) is an acute systemic vasculitis. Both the etiology of KD and the erythema of Bacille Calmette-
Guérin (BCG) injection sites observed in the disease are poorly understood. We investigated the association between KD and single 
nucleotide polymorphisms (SNPs) in two candidate genes: inositol 1,4,5-triphosphate 3-kinase (ITPKC), a well-studied KD-asso-
ciated gene, and solute carrier 11a1 (SLC11A1), which is associated with the hypersensitive reaction to the BCG strain in Koreans.
Materials and Methods: Associations between KD and SNPs in two genes were evaluated. Potential associations between BCG 
injection site erythema and SNPs in two genes were also evaluated. Gene-gene interactions between ITPKC and SLC11A1 in KD 
and BCG injection site erythema were also analyzed. 
Results: Three tagging SNPs in ITPKC and five tagging SNPs in SLC11A1 were genotyped in 299 KD patients and 210 control chil-
dren. SNP rs28493229 in ITPKC was associated with KD and coronary artery complications. SNP rs77624405 in SLC11A1 was as-
sociated with KD. Comparisons of KD patients with and without BCG injection site erythema revealed that SNP rs17235409 in 
SLC11A1 was associated with erythema; no erythema-associated SNPs in ITPKC were identified. Interactions between ITPKC 
rs28493229_GG and SLC11A1 rs17235409_GA and between ITPKC rs10420685_GG and SLC11A1 rs17235409_AA were strongly 
associated with BCG injection site erythema. 
Conclusion: This study identified several important polymorphisms in the ITPKC and SLC11A1 genes in Koreans. The genetic 
variants identified in this study affected KD and erythema of BCG injection sites independently and through gene-gene interac-
tions. Also, the effects of the polymorphisms were age-dependent.
Key Words: Kawasaki disease, Korean, polymorphism, gene-gene interaction, ITPKC gene, SLC11A1 gene 
INTRODUCTION
Kawasaki disease (KD) is an acute systemic vasculitis that pri-
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marily affects children younger than 5 years of age. There are 
no specific laboratory tests for the diagnosis of KD; therefore, 
diagnosis is usually made according to clinical criteria.1 Fol-
lowing Japan, Korea has the second highest prevalence of KD 
in the world, and the incidence of this disease is increasing 
steadily.2 Although KD is a self-limiting disease, if not treated 
properly with intravenous immune globulin (IVIG), coronary 
artery lesions (CALs) can occur. In developed countries, KD is 
the most common cause of acquired heart disease. 
KD exhibits an epidemic pattern. The peak incidence is at 
9−11 months of age, coinciding with waning maternal immu-
nity. Symptoms are similar to those of other infectious diseas-
es, and the course of disease is usually self-limited. For these 
reasons, KD was once thought to be an infectious disease. Sev-
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eral organisms were reported as causative agents, including 
viruses and species of some bacteria, such as Streptococcus and 
Staphylococcus. However, no causative infectious organisms 
have been isolated from patients.3
Genetic predisposition to KD has also been suggested. The 
annual incidence of KD worldwide is highest and is increas-
ing in Japan, Korea, and Taiwan. This incidence is 10−20 times 
higher than that of Western countries. Interestingly, the same 
incidence level in people of Japanese ancestry living in Hawaii 
indicates that the predilection for Asian populations may not 
be due solely to geographic factors. KD also exhibits familial 
disposition. The relative risk for siblings is about 10-fold greater, 
and a recent study revealed that two-generation KD patients is 
more prevalent than expected. HLA types and allotypes of im-
munoglobulin in relation to KD have been studied, although 
results differ by study and region. Lack of agreement between 
studies may be due to differences in genetic background 
among the different races involved. Thus, KD can be thought of 
as a complex multifactorial disease that develops in associa-
tion with unidentified infectious organisms in children with a 
predisposing genetic background.4 
With the recent advent of genome-wide association studies, 
remarkable progress has been made in identifying candidate 
genes associated with KD.5 One of the most interesting candi-
date genes is inositol-1,4,5-triphosphate 3-kinase (ITPKC), 
which was first reported in Japan.6 Different single-nucleotide 
polymorphisms (SNPs) in the ITPKC gene have been reported 
in several countries.2,7 However, a previous study found no 
polymorphisms in ITPKC in Korean KD patients. Interestingly, 
a recent study reported that polymorphisms in ITPKC are asso-
ciated with reactivation of Bacille Calmette-Guérin (BCG) in-
jection scars.8
Erythema and induration of the BCG injection site is a spe-
cific clinical feature of KD9,10 and is present in approximately 
30−50% of KD patients, especially in children who are younger 
than 2 years of age.11-13 Although erythematous changes in the 
BCG inoculation site in patients with human herpes virus type 
6 infection have been reported,14 this clinical feature is known 
as a specific finding of KD. Chun, et al.15 used BCG in the de-
velopment of an animal model of KD in programmed death-1 
gene knockout mice. These findings suggest a possible corre-
lation between BCG and the pathogenesis of KD. 
In inbred mice, resistance and susceptibility to the growth 
of BCG is controlled by the BCG locus, also known as the nat-
ural resistance-associated macrophage protein 1 (NRAMP1) 
gene. The NRAMP1 gene was later renamed solute carrier 
11a1 (SLC11A1), and the human homologue was subsequently 
isolated. Interactions of macrophages with bacterial lipopoly-
saccharide and/or natural killer cell−or T cell−derived inter-
feron-γ are regulated by SLC11A1. Polymorphisms in SCL11A1 
are thought to induce a hypersensitivity reaction to the BCG 
strain. A relationship between SCL11A1 polymorphisms and 
KD has been reported.16
This study examined polymorphisms in the ITPCK gene in 
Korean patients with KD. Polymorphisms in SLC11A1 were 
also examined to determine a possible association with KD. 
The relationship between KD susceptibility and polymor-
phisms in these genes was also examined. As other studies 
have investigated interactions between these two genes, espe-
cially with respect to synergistic effects,17,18 gene-gene interac-
tions and/or synergistic effects between SCL11A1 and ITPKC 
polymorphisms in KD were also investigated. 
MATERIALS AND METHODS
Subject groups
We evaluated 299 patients with typical KD who were admitted 
to Severance Children’s Hospital between January 1, 2012 and 
October 31, 2015. The patients were diagnosed using criteria 
of the Japanese Kawasaki Disease Research Committee.19 In-
complete or atypical KD cases were excluded. The control 
group included healthy children who had no past history of KD 
and had visited the endocrinology clinic of our hospital for 
cosmetic reasons. 
The KD patients were dichotomized based on age: below or 
over the age of 24 months, since erythema of BCG sites is pre-
dominantly observed in children younger than 24 months. 
This study was approved by the Institutional Review Board 
Ethics Committee of Yonsei University College of Medicine 
(2008-0055-010). 
Genomic DNA extraction and whole-gene sequencing
Genomic DNA was extracted using a QIAmp DNA Blood Mini 
Kit (QIAGEN, Hilden, Germany). DNA was quantified using 
an Epoch microplate spectrophotometer (BioTek, Winooski, 
VT, USA).
In order to identify causative variants, we sequenced the 
SLC11A1 and ITPKC genes in 24 KD patients less than 24 
months old who appeared to have BCG injection site erythema. 
Genomic sequences for analysis were obtained from the Gen-
Bank (https://www.ncbi.nlm.nih.gov/gene/) database. Poly-
merase chain reaction (PCR) primers for amplifying the exon 
and promoter regions (2 kb upstream from exon 1) of the 
genes were designed using Primer3 software (http://frodo.
wi.mit.edu/primer3/).20 Each amplified PCR fragment was se-
quenced using BigDye Terminator chemistry on an ABI Prism 
3730xl DNA analyzer (Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer’s protocol. The results 
were then expanded to include all KD patients and controls. 
DNA polymorphisms were identified using the PolyPhred 
program (http://droog.gs.washington.edu/polyphred/).21 Tag-
ging SNPs were selected using Haploview version 4.2. Among 
SNPs selected according to whole-gene sequencing of SL-
C11A1 and ITPKC through linkage disequilibrium (LD) analy-
sis, genotyping of tagging SNPs was carried out for all samples 
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using the TaqMan® fluorogenic 5’-nuclease assay (Applied 
Biosystems). The polymorphism rs2290692 was added in the 
3’-UTR of the ITPKC gene, as it was recently identified in Han 
Chinese and is known to be associated with susceptibility to 
KD.22 Real-time PCR was performed using a QuantStudioTM 6 
Flex Real-Time PCR System (Applied Biosystems). After PCR 
and genotyping, the data were analyzed using 7500 SDS 2.3 
software (Applied Biosystems).
Statistical analysis
All statistical analyses were performed using SAS software (ver-
sion 9.0) on a Windows 7 platform. To test for associations with 
KD, Cochran-Armitage trend test (chi-squared test) was used to 
compare allele and genotype frequencies (nominal variables) 
between cases and controls. Student’s t-test was used to ex-
amine the statistical significance of differences between cases 
and controls. Binary logistic regression is used to explain the 
relationship between one dependent binary variable and one 
or more independent variables (genes). A p-value less than 
0.05 was considered indicative of statistical significance. Con-
tinuous variables are expressed in mean±SD, and categorical 
variables are expressed in numbers (%).
Synergistic effects between SLC11A1 and ITPKC genetic poly-
morphisms were analyzed using combination modes of mul-
tiple genetic loci. The search for the best combination pattern 
of the genetic polymorphisms in surveyed genes was carried out 
based on the principle of maximization of both cross-valida-
tion consistency and test balance accuracy in order to evaluate 
interactions between the two genes of interest in relation to KD.
RESULTS
Clinical characteristics of the subjects
A total of 299 KD patients and 210 healthy control children were 
recruited (Table 1). Of the 299 KD patients, 77 (25.75%) patients 
had BCG injection site erythema. When the subjects were di-
chotomized by age above or below 24 months, the percentage 
of patients exhibiting erythema of the BCG site differed (p< 
0.001). A total of 62 of 114 (54.39%) younger patients, who 
were less than 24 months of age, had erythema of the BCG in-
jection site. Among the older subjects, only 15 of 185 (8.11%) 
exhibited BCG injection site erythema. 
KD patients exhibited elevations in white blood cell (WBC) 
count, erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP) level, and lactate dehydrogenase (LDH) level, com-
pared with control participants.
CALs were observed in 55 of 299 patients (18.39%). CALs 
occurred more frequently (p=0.008) in the older age group (42 
of 185 patients, 22.70%), compared with the younger age group 
(13 of 114 patients, 11.40%). 48 patients (16.05%) had recur-
rence of clinical symptoms. However, there was no difference 
in recurrence of clinical symptoms between the older age group 
(30 of 185 patients, 16.22%) and the younger age group (18 of 
114 patients, 15.79%). 
Polymorphisms of ITPKC and SLC11A1 gene and 
associations with clinical or laboratory findings
According to the results of preliminary exon sequencing for 24 
patients, seven SNPs in ITPKC and 10 SNPs in SLC11A1 were 
selected. No novel SNPs were identified. Based on the results 
of LD analyses, four tagging SNPs in ITPKC and five tagging 
SNPs in SLC11A1 were selected. The frequencies for the entire 
study group and the control group are listed in Table 2. 
Comparison of the genotype and allele frequencies in the pa-
tient and control groups revealed a significant difference only 
for rs28493229 in the intron of ITPKC (p=0.045 and p=0.022, 
respectively). Over-representation of the C allele in rs28493229 
of ITPKC was observed (Table 3). Similar results were observed 
in the younger patients after dichotomization based on age 
(p=0.039 and p=0.031, respectively).
Although no significant difference between the experimen-
Table 1. Characteristics of the Study Subjects
Variables
KD patients Controls
(n=210)
p value
All (n=299) <24 month (n=114) ≥24 month (n=185)
Age (month)   41.81±39.49 11.81±5.88   60.33±40.05 115.97±35.24    <0.0001*
Gender (M:F) 194:105 81 (41.8%):33 (31.4%) 113 (58.2%):72 (68.6%) 130:80    <0.0001*
BCG injection site erythema (%) 77 62 (80.5) 15 (19.5) NA <0.001†
WBC 12900.73±5315.07 13594.09±5195.91 12432.82±5359.14 6910.71±201.68    <0.0001*
Platelet   399.97±182.73   425.72±181.55   382.60±182.02 304.70±71.17    <0.0001*
ESR   63.51±32.49   59.93±33.15   65.98±31.90 11.00±9.81    <0.0001*
CRP   57.75±53.02   51.09±47.92   62.33±55.95   9.152±14.61    0.069*
LDH   334.75±145.66   334.06±115.38   335.21±163.21 241.21±41.67    <0.0001*
Coronary complication (%) 55 13 (23.6) 42 (76.4) NA   0.008†
Recur of KD (%) 48 18 (37.5) 30 (62.5) NA   0.296†
KD, Kawasaki disease; BCG, Bacille Calmette-Guérin; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydro-
genase.
*p value for comparison between KD patients and controls, †p value for comparison between <24-month-old KD patients (younger age group) and ≥24-month-
old KD patients (older age group).
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Table 2. Frequency of SNPs in the ITPKC and SLC11A1 Genes for the Patient and Control Groups
Variations (SNPs) Genotypes p value Alleles p value
ITPKC CC CT TT C T
rs2561531
Controls 130 (61.90)   70 (33.33) 10 (4.76)
0.957
330 (78.57) 90 (21.43)
0.856
KD patients 184 (61.54)   99 (33.11) 16 (5.35) 467 (78.09) 131 (21.91)
GG GC CC G C
rs28493229
Controls 178 (84.76)   32 (15.24)   0 (0.00)
0.045
388 (92.38) 32 (7.62)
0.022
KD patients 231 (77.26)   64 (21.40)   4 (1.34) 526 (87.96)   72 (12.04)
AA AG GG A G
rs10420685
Controls 114 (54.29)   76 (36.19) 20 (9.52)
0.836
 304 (72.38) 116 (27.62)
0.777
KD patients 156 (52.17) 116 (38.80) 27 (9.03) 428 (71.57) 170 (28.43)
GG GC CC G C
rs2290692
Controls   65 (30.95)   97 (46.19)   48 (22.86)
0.933
227 (54.05) 193 (45.95)
0.908
KD patients   89 (29.77) 143 (47.83)   67 (22.41) 321 (53.68) 277 (46.32)
SLC11A1 CC CT TT C T
rs7573065
Controls 194 (92.38)   15 (7.14)   1 (0.48)
0.405
403 (95.95) 17 (4.05)
0.815
KD patients 273 (91.30)   26 (8.70)   0 (0.00) 572 (95.65) 26 (4.35)
GG GA AA G A
rs2276631
Controls 143 (68.10)   59 (28.10)   8 (3.81)
0.909
345 (82.14)   75 (17.86)
0.688
KD patients 209 (69.90)   79 (26.42) 11 (3.68) 497 (83.11) 101 (16.89)
CC CT TT C T
r17221959
Controls 186 (88.57)   24 (11.43)   0 (0.00)
0.202
396 (94.29) 24 (5.71)
0.220
KD patients 253 (84.62)   46 (15.38)   0 (0.00) 552 (92.31) 46 (7.69)
GG GA AA G A
rs77624405
Controls 204 (97.14)     6 (2.86)   0 (0.00)
0.072
414 (98.57)   6 (1.43)
0.076
KD patients 280 (93.65)   19 (6.35)   0 (0.00) 579 (96.82) 19 (3.18)
GG GA AA G A
rs17235409
Controls 165 (78.57)   42 (20.00)   3 (1.43)
0.886
372 (88.57)   48 (11.43)
0.780
KD patients 239 (79.93)   55 (18.39)   5 (1.67) 533 (89.13)   65 (10.87)
SNPs, single nucleotide polymorphisms; ITPKC, inositol 1,4,5-triphosphate 3-kinase; SLC11A1, solute carrier 11a1; KD, Kawasaki disease.
Table 3. Frequencies of ITPKC rs28493229
Phenotype
Genotypes
p value
Alleles
p value
GG GC CC G C
All
Controls 178 (84.76) 32 (15.24) 0 (0.00)
0.045
388 (92.38) 32 (7.62)
0.022
KD patients 231 (77.26) 64 (21.40) 4 (1.34) 526 (87.96)   72 (12.04)
<24 months
Controls 178 (84.76) 32 (15.24) 0 (0.00)
0.039
388 (92.38) 32 (7.62)
0.031
KD patients   86 (75.44) 27 (23.68) 1 (0.88) 199 (87.28)   29 (12.71)
≥24 months
Controls 178 (84.76) 32 (15.24) 0 (0.00)
0.065
388 (92.38) 32 (7.62)
0.052
KD patients 145 (78.38) 37 (20.00) 3 (1.62) 327 (88.38)   43 (11.62)
ITPKC, inositol 1,4,5-triphosphate 3-kinase; KD, Kawasaki disease.
Table 4. Frequencies of SLC11A1 rs77624405
Phenotype
Genotypes
p value
Alleles
p value
GG GA G A
All
Controls 204 (97.14) 6 (2.86)
0.072
414 (98.57) 6 (1.43)
0.076
KD patients 280 (93.65) 19 (6.35) 579 (96.82) 19 (3.18)
<24 months
Controls 204 (97.14) 6 (2.86)
0.008
414 (98.57) 6 (1.43)
0.009
KD patients 103 (90.35) 11 (9.65) 217 (95.18) 11 (4.82)
≥24 months
Controls 204 (97.14) 6 (2.86)
0.425
414 (98.57) 6 (1.43)
0.429
KD patients 177 (95.68) 8 (4.32) 362 (97.84) 8 (2.16)
SLC11A1, solute carrier 11a1; KD, Kawasaki disease.
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tal and control groups was observed for rs77624405 in exon 12 
of SLC11A1, when the patients were dichotomized, a signifi-
cant difference was found in the younger patients (p=0.008 and 
p=0.009, respectively). Overrepresentation of the A allele in 
rs77624405 of the SLC11A1 gene was observed (Table 4). 
The relationship between the identified SNPs and laboratory 
data was also assessed. The laboratory data differed between 
the KD patients and normal controls, and the alleles of the re-
lated SNPs were heterogeneous.
The rs2290692 polymorphism in ITPKC was associated with 
elevations in WBC, platelet counts, and LDH levels in the KD 
group, compared with those of the control group. When the 
KD group was dichotomized based on age above and below 
24 months, a different polymorphism pattern was observed. In 
the younger patients, elevations in WBC count and LDH level 
were associated with different SNPs, compared with the non-
dichotomized KD group. The rs28493229 polymorphism was 
associated with elevated WBC counts, and the rs10420685 po-
lymorphism was associated with elevated LDH levels in the 
younger patients. Elevated platelet levels in the younger pa-
tients were associated with the same rs28493229 SNP, similar 
to the non-dichotomized KD group. Elevated ESR was associ-
ated with polymorphism rs2290692 in the younger patients, 
but not in the non-dichotomized KD group. In the older patients, 
polymorphism rs2290692 was associated with elevated WBC 
counts, similar to the non-dichotomized KD group. Polymor-
phism rs28493229 was associated with elevated platelet counts 
in the older patients, a pattern that differed compared with 
that of the non-dichotomized KD group and younger patients.
Polymorphism of rs17235409 in SLC111A1 was associated 
with elevated LDH in the older age group, and polymorphism 
of rs2276631 in SLC11A1 was associated with increased as-
partate aminotransferase levels in the younger age group. Be-
sides these two polymorphisms of SLC11A1, no SNP sites in 
SLC11A1 were related with inflammatory markers (Table 5).
Interactions between the ITPKC and SLC11A1 genes 
in KD patients
When comparing the KD patients and controls, no significant 
interactions between the ITPKC and SLC11A1 genes were ob-
served. However, after the KD patients were dichotomized 
based on age above and below 24 months, interactions be-
tween ITPKC rs2561531 CC and SLC11A1 rs17221959 CT and 
between ITPKC rs2561531 CC and SLC11A1 rs77624405 GA 
appeared to exert a protective effect against KD symptoms in 
the younger patients (Table 6).
Associations of polymorphisms in the ITPKC and 
SLC11A1 genes with BCG injection site erythema
No SNPs exhibiting a relationship with BCG injection site ery-
Table 5. Association between Laboratory Data and Polymorphisms in the ITPKC and SLC11A1 Genes
Phenotype SNP Values p value
ITPKC gene
KD vs. control
rs2290692_GC Elevation of WBC   0.021
rs2290692_GC Elevation of platelet   0.024
rs2290692_CC Elevation of LDH   0.040
<24 months vs. controls
rs28493229_CC Elevation of WBC <0.001
rs2290692_GC Elevation of platelet   0.046
rs2290692_GC Elevation of ESR   0.025
rs10420685_AG Elevation of LDH   0.014
≥24 months vs. controls
rs2290692_GC Elevation of WBC   0.033
rs28493229_CC Elevation of platelet   0.008
SLC11A1 gene
<24 months vs. controls rs2276631_GA Elevation of AST   0.022
≥24 months vs. controls rs17235409_GA Elevation of LDH   0.050
ITPKC, inositol 1,4,5-triphosphate 3-kinase; SLC11A1, solute carrier 11a1; SNPs, single nucleotide polymorphisms; KD, Kawasaki disease; WBC, white blood 
cell; LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransferase
Table 6. Gene-Gene Interactions between the ITPKC and SLC11A1 Genes in KD Patients
Phenotype/genotype OR (95% CI) p value 
All
ITPKC rs2561531_CC   SLC11A1 rs17221959_CT 0.841 (0.387−1.828) 0.661
ITPKC rs2561531_CC   SLC11A1 rs77624405_GA 0.249 (0.047−1.328) 0.104
<24 months
ITPKC rs2561531_CC SLC11A1 rs17221959_CT 0.379 (0.154−0.931) 0.034
ITPKC rs2561531_CC SLC11A1 rs77624405_GA 0.128 (0.025−0.667) 0.015
ITPKC, inositol 1,4,5-triphosphate 3-kinase; SLC11A1, solute carrier 11a1; KD, Kawasaki disease; OR, odds ratio; CI, confidence interval.
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thema were found in ITPKC in the KD group. Polymorphism 
rs17235409 in SLC11A1 exhibited a relationship with BCG in-
jection site erythema only in the younger-age KD patients 
(Table 7). 
Association of ITPKC and SLC11A1 gene interactions 
with BCG injection site erythema in KD patients
As shown in Table 8, statistically significant associations were 
found for interactions between rs28493229 of ITPKC and 
rs17235409 of SLC11A1 [odds ratio (OR)=5.1; p=0.017] and 
between rs10420685 of ITPKC and rs7235409 of SLC11A1 
(OR=12.51; p=0.008) in the older-age KD patients. 
Associations of polymorphisms in the ITPKC and 
SLC11A1 genes with CALs and clinical symptom 
recurrence
As shown in Table 9, polymorphism rs28493229 in ITPKC was 
associated with CALs. However, no ITPKC or SLC11A1 SNPs 
were found to be associated with the recurrence of clinical 
symptoms.
DISCUSSION
The KD-associated gene ITPKC was first identified and studied 
in Japan.6 Many studies have shown relatively higher frequen-
cies of ITPKC in Japanese (0.16) and European populations 
(0.15), compared with Taiwanese populations (0.054).7 Con-
sistent with geographic differences in SNPs, one study con-
ducted in Korea did not find similar polymorphisms in ITPKC.23 
In the present study, KD was carefully classified and an appro-
priate control group was selected to ensure the validity of the 
results. Patients with atypical or incomplete KD were thus ex-
cluded, as were those treated with IVIG before the fourth day 
of fever. In the present study, a significant increase in the fre-
quency of allele C in rs28493229 was found in KD patients over-
all. The same increase was observed in KD patients younger 
than 24 months. Contrary to previous reports from Korea, this 
result demonstrated that polymorphisms in ITPKC are indeed 
associated with KD in Korea. However, the frequency was low 
(0.12), compared with that reported for other countries, includ-
ing Japan (0.16).7 
rs28493229 polymorphism in ITPKC was also significantly 
associated with CALs. In our study, only genotype showed a 
statistically significant difference but not in alleles. Onouchi7 re-
ported a significant relationship between the C allele and CALs. 
In the present study, however, the frequency of the C allele was 
higher in CALs, although no statistically significant difference 
was found. In contrast, the same SNP in Taiwanese children 
was not significantly associated with CALs. These results provide 
some explanation for the variety of country-specific SNPs.8,24
A number of inflammatory markers, such as ESR, CRP, WBC, 
platelets, and LDH, are typically elevated in the peripheral 
Table 7. Association of the rs17235409 Polymorphism in SLC11A1 with 
BCG Injection Site Erythema
Genotypes BCG (+) Control p value
All
GG   62 (80.52) 155 (78.68)
0.900GA   14 (18.18)   38 (19.29)
AA   1 (1.30)   4 (2.03)
G 138 (89.61) 348 (88.32)
0.669
A   16 (10.39)   46 (11.68)
<24 months
GG   53 (85.48)   32 (66.67)
0.037GA     8 (12.90)   15 (31.25)
AA   1 (1.61)   1 (2.08)
G 114 (91.94)   79 (82.29)
0.031
A 10 (8.06)   17 (17.71)
SLC11A1, solute carrier 11a1; BCG, Bacille Calmette-Guérin.
Table 8. Gene-Gene Interactions of ITPKC and SLC11A1 Genes with BCG Injection Site Erythema
Phenotype/genotype OR (95% CI) p value  
All
ITPKC rs28493229_GG SLC11A1 rs17235409_GA 0.031 (0.093−1.031) 0.056
ITPKC rs10420685_GG SLC11A1 rs17235409_AA <0.001 (<0.001 − <999.999) 0.985
≥24 months
ITPKC rs28493229_GG SLC11A1 rs17235409_GA 5.105 (1.345−19.372) 0.017
ITPKC rs10420685_GG SLC11A1 rs17235409_AA 12.51 (1.927−82.01) 0.008
ITPKC, inositol 1,4,5-triphosphate 3-kinase; SLC11A1, solute carrier 11a1; BCG, Bacille Calmette-Guérin; OR, odds ratio; CI, confidence interval.
Table 9. Relationship between the ITPKC Polymorphism rs28493229 and CALs
Phenotype
Genotypes
p value
Alleles
p value
GG GC CC G C
All 0.043 0.087
No CAL patients 181 (78.35) 49 (21.21) 1 (0.43) 411 (88.96) 51 (11.04)
CAL patients 40 (72.73) 12 (21.82) 3 (5.45) 92 (83.64) 18 (16.36)
ITPKC, inositol 1,4,5-triphosphate 3-kinase; CAL, coronary artery lesion.
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blood of KD patients during the acute phase of the disease. The 
patients in the present study also exhibited increased WBC 
and platelet counts, as well as elevated LDH, CRP levels, and 
ESR levels. A previous study reported no significant correla-
tions between SNPs in ITPKC and various inflammatory mark-
ers.8 In the present study, however, several polymorphisms in 
ITPKC and SLC11A1 were associated with elevations in WBC 
and platelet counts, as well as LDH levels, in the KD group rel-
ative to the controls, as shown in Table 5. The association with 
elevated inflammatory markers was more pronounced for poly-
morphisms in SLC11A1, compared with those in ITPKC. Fur-
thermore, this association differed in older and younger patients.
The results of this study suggest that KD is not a single disease 
entity. Differences in age of onset, clinical feature, pattern of 
laboratory data, and response to IVIG treatment in conjunction 
with age-related differences in SNPs suggest that KD would 
be more appropriately designated Kawasaki ‘syndrome’, as it 
more closely resembles a group of heterogeneous entities that 
present a similar clinical picture. 
A typical laboratory finding in KD is elevated platelet counts. 
This is very important, because low-dose aspirin treatment is 
used to prevent thrombosis associated with elevations in plate-
let count. The exact mechanism underlying the development 
of thrombocytosis in KD is unknown. Speculatively an increase 
in serum interleukin (IL)-6 levels during the acute phase of the 
disease triggers megakaryocyte maturation in the bone mar-
row, resulting in an increase in the number of platelets in the 
peripheral blood.25 According to our data, SNPs in ITPKC (but 
not SLC11A1) are associated with thrombocytosis. These re-
sults indicate that ITPKC is more closely associated with inflam-
mation in KD than SLC11A1.
Another interesting finding of the present study is that poly-
morphism rs28493229 in ITPKC has a protective effect against 
KD symptoms [OR 0.563; 95% confidence interval (CI) 0.343− 
0.923; p=0.022]. We expected that the most-studied ITPKC SNP 
rs28493229 would instead have a triggering effect on KD.26 
Some studies have shown no association between KD and 
polymorphism rs28493229 in ITPKC.27 However, the opposite 
effect was observed in the present study. Along with the previ-
ously mentioned increases in many inflammatory cytokines 
during the acute phase of KD, there is a simultaneous increase 
in the production of the anti-inflammatory cytokine IL-10.5,26,28 
A number of systems within the human body contribute to the 
maintenance of homeostasis. When inflammation in the body 
arises, anti-inflammatory processes work simultaneously to 
restore homeostasis. Considering this context, the rs28493229 
polymorphism in ITPKC may play a role in suppressing the ini-
tial symptoms of KD as a means of maintaining homeostasis. 
In the process of choosing tagging SNPs, we added rs2290692 
in the 3’-UTR of ITPKC. Han Chinese KD patients have a higher 
frequencies of the C allele (p<0.001), compared with disease-
free participants.22 However, no statistically significant differ-
ence in C-allele frequency between KD patients and controls 
was observed in the present study. This result further demon-
strates the geographic differences in the genetic background 
of KD.
The SLC11A1 gene was originally named NRAMP1. SLC11A1 
encodes an iron-transporting protein that plays an important 
role in controlling susceptibility to Mycobacterium tuberculo-
sis infection via regulation of IL-1 and TNF production, as well 
as the activation of macrophages. With respect to BCG, it iden-
tifies host genes and proteins that play a key role in the re-
sponse to mycobacterial infections.29 As BCG injection site er-
ythema is most common in younger KD patients, we searched 
for polymorphisms in this gene and found a total of 15 SNPs. 
Ouchi, et al.16 showed that one variant of the SLC11A1 gene is 
associated with KD in Japan. However, they could not find any 
polymorphisms in the SLC11A1 gene, perhaps due to the age 
of the KD patients enrolled in the study. In contrast to Ouchi, 
et al.,16 who did not consider the age of patients in their analysis, 
in our study, KD patients were dichotomized based on age less 
than and more than 24 months. In comparing the KD group 
as a whole with controls, no polymorphisms in SLC11A1 were 
found, in agreement with the study of Ouchi, et al.16 However, 
when KD patients under 24 months of age were considered, a 
statistically significant polymorphism, rs77624405, was identi-
fied, suggesting that this polymorphism in SLC11A1 is associ-
ated with KD in patients under 24 months of age. This finding 
correlates well with the observed frequency of BCG injection 
site erythema in patients under 24 months of age. Compared 
with control subjects, KD patients under 24 months of age 
tended to have a higher frequency of the A allele in rs2276631, 
whereas KD patients over 24 months of age tended to have a 
higher frequency of the A allele in rs17235409. 
Gene-gene interactions have been linked to a number of 
important diseases, such as diabetes and essential hyperten-
sion.30,31 In KD, interactions between ITPKC and the caspase-3 
gene have been studied with respect to an association be-
tween unresponsiveness of IVIG and development of coro-
nary artery complications.32,33 The potential role of interac-
tions between ITPKC and SLC11A1 was therefore examined 
in the present study. No meaningful interactions between 
these two genes were observed when the overall KD and con-
trol groups were analyzed. However, interactions between 
rs2561531 in ITPKC and rs17221959 in SLC11A1 and between 
rs2561531 in ITPKC and rs77624405 in SLC11A1 were found 
when the KD patients were considered based on age above 
and below 24 months, and these interactions were found to 
have a protective effect. The rs2561531 polymorphism in ITP-
KC is particularly interesting. This SNP was not identified in 
analyses of ITPKC in the KD patients. In analyses of potential 
associations between ITPKC and SLC11A1, however, a role for 
rs2561531 in ITPKC was revealed. Roles for rs17221959 and 
rs77624405 in SLC11A1 were also identified.
Although BCG injection site erythema is not included in the 
diagnostic criteria for KD, it is an important clue, as there is no 
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other disease associated with erythematous changes at the 
BCG injection site. In a previous report, Lin, et al.8 concluded 
that there is an association between the C allele of ITPKC SNP 
rs28493229 and BCG scars, although the frequency is low 
(8.04%). However, in the present study, the C allele of ITPKC 
SNP rs28493229 was not significantly associated with BCG in-
jection site erythema.
In younger KD patients, the SLC11A1 SNP rs17235409 was 
associated with BCG injection site erythema. Although one 
Japanese study reported no polymorphisms in SLC11A1,16 the 
results may have been affected by differences in nationality, 
year of introduction of BCG vaccination, or BCG coverage rate. 
A comparison of patients of all ages with and without BCG in-
jection site erythema indicated that SLC11A1 SNP rs2276631 
was associated with a decreased risk of KD (OR 0.161; 95% CI 
0.038−0.689; p=0.014). In patients less than 24 months of age, 
however, the SLC11A1 SNP rs17235409 was associated with 
increased risk of KD (OR 2.483; 95% CI 1.063−5.804; p=0.036). 
The SLC11A1 gene is known to be associated with autoim-
mune and infectious diseases. The SNPs analyzed in this study 
are associated more with infectious than autoimmune disease. 
The SNPs rs7573065, rs2276631, rs17221959, and rs17235409 
in SLC11A1 are associated with tuberculosis and infection 
with Mycobacterium spp., with one meta-analysis reporting 
estimated OR >1.34 As BCG immunization is given to children 
at less than 1 month of age, the association of these SNPs with 
KD may be more significant in younger children.
Analyses of interactions between ITPKC and SLC11A1 showed 
a synergistic effect for BCG injection site erythema in patients 
over 24 months of age. Interactions between rs28493229 in IT-
PKC and rs17235409 in SLC11A1 and between rs10420685 in 
ITPKC and rs7235409 in SLC11A1 may trigger erythema in 
BCG injection sites. These results indicate that reactivation of 
BCG scars is associated with polymorphisms in either ITPKC 
or SLC11A1 in patients under 24 months of age. However, in 
patients older than 24 months, reactivation of BCG scars is as-
sociated with synergism between the polymorphisms of these 
two genes rather than either of the genes alone.
During the acute phase of KD, striking immunological de-
rangements occur, including changes in immune cells and 
marked inflammatory cytokine cascade stimulation.3 In light 
of these changes, Kim3 suggested that acquired immune re-
sponses play an important role in the development of KD. Re-
cently, Ikeda, et al.35 suggested that innate immunity, rather 
than acquired immunity, plays an important role in the devel-
opment of vasculitis in KD. Kusuda, et al.36 reported that KD-
specific molecules in the serum possess structures common 
to microbe-associated molecular pattern (MAMP) molecules 
of bacteria, such as Bacillus, Yersinia, and Staphylococcus, and 
that levels of these molecules decline after IVIG treatment. 
Hara37 suggested that increased levels of MAMP and damage-
associated molecular pattern (DAMP) molecules in the serum 
of acute-phase KD patients activate the immune system and 
vascular cells through innate immune pattern recognition re-
ceptors, leading to the release of various cytokines. Heat shock 
protein, which is contained in considerable amounts in the 
BCG vaccine, is a well-known DAMP. It can thus be speculat-
ed that BCG-associated DAMPs play an important role in the 
development of KD.
Many researchers have concluded that the innate immune 
system is present at birth and does not change throughout 
one’s life.38 However, the results of the present study indicate 
that KD is associated with a difference in genetic background 
with respect to various inflammatory markers and reactivation 
of BCG scars in patients younger and older than 24 months. In-
terestingly, increasing evidence indicates that there are age-as-
sociated differences in the maturation and function of the in-
nate immune system.39,40 In light of these factors, the results of 
the present study show that age-associated differences in BCG 
injection site erythema and genetic background in patients 
with KD are reasonable.
It is unclear whether BCG itself induces KD or the BCG in-
jection site is reactivated as a result of specific processes that 
occur during initiation of KD or possibly whether reactivation 
of the BCG injection site is caused by the suppression of the in-
flammation process in KD. Nevertheless, it is clear that the BCG 
injection site exhibits inflammatory changes that manifest as 
erythema. Further study is needed to clarify the relationship 
between BCG injection site erythema and KD, as demonstrat-
ed by Chun, et al.15
This study has several limitations. First, the study was not con-
ducted at the functional gene level. Second, the power of the 
study was low. Third, the control group was not age-matched. 
However, it was concluded that age matching would not signifi-
cantly impact the results, as future development of KD in young, 
healthy children cannot be ruled out. Therefore, older patients 
without a history of KD were considered a better choice for the 
control group. 
In conclusion, this study identified polymorphisms in the 
ITPKC and SLC11A1 genes in Korean KD patients. These poly-
morphisms were associated with increased production of in-
flammatory markers in the peripheral blood of patients with 
KD. The SNPs identified in this study were also associated with 
erythema of the BCG injection site in KD patients, although 
their effects differed depending on age of patients.
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